$10,173.51 speaking Payment -- Sanofi to Dr. Melissa Reed

Sanofi Compensates Rheumatologist Dr. Melissa Reed for Speaking Services

This page provides a detailed analysis of a $10,173.51 speaking payment from Sanofi to Dr. Melissa Reed. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

Field	Value
Amount	$10,173.51
Payment Type	speaking
Payment Nature	Compensation for serving as faculty or as a speaker
Pharmaceutical Company	Sanofi
Physician	Dr. Melissa Reed
NPI Number	1298881451
Physician Specialty	Rheumatology
Location	Peoria, IL
Date of Payment	2025-01-20
Conflict Assessment	Low -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Sanofi made a $10.2K speaking payment to Melissa Reed, a Rheumatology specialist in Peoria, IL. Sanofi paid Dr. Melissa Reed $10,173.51 on January 20, 2025, for speaking engagements. The payment was for Dr. Reed's role as faculty or speaker. This payment falls under the 'speaking' category of the CMS Open Payments program.

Patient Guidance: What This Payment Means for You

This payment information is for transparency and does not necessarily indicate an endorsement of any product or service. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Payments for speaking engagements are common in the pharmaceutical industry, with amounts varying based on the nature of the engagement and the speaker's expertise.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Physician Payments Sunshine Act, part of the Affordable Care Act, which requires manufacturers of drugs and medical devices to report payments made to physicians and teaching hospitals.

Understanding speaking Payments

Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.

Frequently Asked Questions About This Payment

What was this $10.2K payment for?

This was a speaking payment of $10.2K from Sanofi to Melissa Reed, categorized as "Compensation for serving as faculty or as a speaker". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Melissa Reed accept pharmaceutical money?

Yes, Melissa Reed received this $10.2K payment from Sanofi. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Melissa Reed's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this speaking payment?

A speaking payment of $10.2K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rheumatology?

To compare this payment against Rheumatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rheumatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Melissa Reed's relationship with Sanofi?

The payment amount is $10,173.51. This $10.2K speaking payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rheumatology?

The payment date is January 20, 2025.

What should patients do after learning about this payment?

This payment information is for transparency and does not necessarily indicate an endorsement of any product or service.

What else should I know about this speaking payment?

The payment was made by Sanofi.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.